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Corrigendum
Sailasuta N, Harris K, Tran T, Ross B. Minimally invasive 
biomarker confirms glial activation present in Alzheimer’s disease: 
a preliminary study. Neuropsychiatr Dis Treat. 2011;7:495–499.
Abstract: The third sentence should be ‘Calculation of the 
initial slope was similar in a single subject, examined twice, 
4 months apart (test–retest 8%).’
Methods, ‘Patients’ section: The second line should be 
‘A total of 24 MRI/MRS studies were performed on five 
Table 1 Compilations of subjects’ characteristics, proton, carbon MrS, and neuropsychological assessment results
Patient 1 
control
Patient 2 
control
Patient 3 
MCI
Patient 4 
MCI
Patient 5A* 
AD
Patient 5B* 
AD
Subject characteristics
  Age 80 83 77 81 76
  gender M M M M F
  MMSe 30 28 26 27 22
Proton MrS results
  NAA/Cr 1.45 1.37 1.47 1.37 1.62 1.39
  mi/Cr 0.56 0.72 0.77 0.74 0.85 0.83
  NAA/mi 2.6 1.92 1.92 1.85 1.34 1.67
Carbon MrS results
    rate of bicarbonate 
production (% Fe/minute)
0.023 0.03 0.042 0.033 0.056 0.06
Neuropsychological assessment (Z scores)
    Attention/concentration 
Working memory
WNL WNL -2 WNL -1.6 -1.6
    Psychomotor/information 
processing
WNL WNL WNL WNL -1.5 -1.5
  Language functions WNL WNL -1.5 WNL -1.5 -1.5
  Verbal memory WNL WNL -1.3 -1.3 -3 -3
  Nonverbal memory WNL WNL -3 WNL -3 -3
    Visuospatial/construction WNL -1.4 -1.4 -2 -2 -2
  executive functions WNL -1.4 -2.5 WNL -3 -3
  Motor functions WNL WNL -1.3 WNL WNL WNL
Notes: *The AD subject was examined twice with a 4-month interval between studies.
Abbreviations: AD, Alzheimer’s disease; Cr, creatine; Fe, fractional enrichment; mi, myo-inositol; MCi, mild cognitive impairment; MMSe, mini-mental state examination; 
MrS, magnetic resonance spectroscopy; NAA, N-acetyl aspartate; WNL, within normal limits.
subjects of whom one had AD, two had mild cognitive 
impairment (MCI) and two were healthy older adults with 
mean age of 78 ± 3 years, and two were females. The AD 
subject was examined twice.’
Methods, ‘Neuroimaging and Spectroscopy’ section: The 
following sentence should be added to the end, ‘Test–retest 
of 13C MRS in an AD was performed at 4 months with 
reproducibility of 8%.’
Table 1 has been revised, as shown below.